Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan
Abstract REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Journal of Intensive Care - 9(2021), 1 vom: 14. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kamata, Kazuhiro [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1186/s40560-021-00547-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2124923501 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2124923501 | ||
| 003 | DE-627 | ||
| 005 | 20240410142928.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230505s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40560-021-00547-7 |2 doi | |
| 035 | |a (DE-627)OLC2124923501 | ||
| 035 | |a (DE-He213)s40560-021-00547-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Kamata, Kazuhiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Abstract REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies. | ||
| 650 | 4 | |a Randomized controlled trial | |
| 650 | 4 | |a REMAP-CAP (Randomized | |
| 650 | 4 | |a Embedded | |
| 650 | 4 | |a Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia) | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Emerging infectious disease | |
| 700 | 1 | |a Jindai, Kazuaki |0 (orcid)0000-0003-4679-3862 |4 aut | |
| 700 | 1 | |a Ichihara, Nao |4 aut | |
| 700 | 1 | |a Saito, Hiroki |4 aut | |
| 700 | 1 | |a Kato, Hideaki |4 aut | |
| 700 | 1 | |a Kunishima, Hiroyuki |4 aut | |
| 700 | 1 | |a Shintani, Ayumi |4 aut | |
| 700 | 1 | |a Nishida, Osamu |4 aut | |
| 700 | 1 | |a Fujitani, Shigeki |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Intensive Care |d BioMed Central, 2013 |g 9(2021), 1 vom: 14. Apr. |h Online-Ressource |w (DE-627)771390440 |w (DE-600)2739853-5 |w (DE-576)395914329 |x 2052-0492 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:1 |g day:14 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40560-021-00547-7 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 1 |b 14 |c 04 | ||